We are now in an era of an FDA approved prophylactic HPV16/18 vaccine for the two major types of HPV causing cervix cancer. Nevertheless, there are many critical questions about the natural history of non-HPV16/18 HPV types associated with cervix cancer and the fine specificity of the vaccine that remain and need to be addressed. The central hypothesis of this application is that DNA mutation and natural selection have driven the evolution of success amongst HPV infections resulting also in the emergence of cancer causing viruses, as a byproduct of filling a specific biological niche. We will utilize epidemiological methods and the analytic tools of evolution and systems biology to study the role of oncogenic HPV types and variants in population-based studies of HPV natural history and cervix neoplasia. We propose 3 specific aims: (1) To define the natural history of the a7 (18-related) and a9 (16-related) HPV types in the HPV Persistence and Progression (PaP) Cohort at Kaiser Permanente Northern California, a new cohort study of 35,000 HR-HPV positive (HC2+) women z 30 yrs of age women and in the 21,000 women from the Portland study with 16 years of follow-up;(2) To determine vaccine efficacy for HPV16/18-variants and related type variants after vaccination with HPV16/18 VLPs in the Costa Rica Vaccine Trial (CVT), a phase III HPV 16/18 vaccine trial of 7500 women 18-25 years of age in Guanacaste;and (3) To identify the genetic basis for the oncogenicity of high-risk HPV types and variants. There is a gradient of oncogenic risk from the most oncogenic, HPV16, to less oncogenic types (e.g., HPV31/35/45/56) to non-oncogenic (e.g., HPV53/70) HPV types within the """"""""oncogenic"""""""" species groups a.5-7, a9 and a11. We will infer full viral genome sequence from variant """"""""haplotype"""""""" information. This data will be combined with pathologic state and/or case-control status from the results generated in the cohort studies to determine genotype-phenotype relationships using a variety of phylogenetic and analytic approaches. Overall the data will provide important information on phenotypic-genetic relationships.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA078527-15
Application #
8272685
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Program Officer
Starks, Vaurice
Project Start
1998-07-24
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2014-04-30
Support Year
15
Fiscal Year
2012
Total Cost
$567,757
Indirect Cost
$225,735
Name
Albert Einstein College of Medicine
Department
Pediatrics
Type
Schools of Medicine
DUNS #
110521739
City
Bronx
State
NY
Country
United States
Zip Code
10461
Chen, Zigui; Schiffman, Mark; Herrero, Rolando et al. (2018) Classification and evolution of human papillomavirus genome variants: Alpha-5 (HPV26, 51, 69, 82), Alpha-6 (HPV30, 53, 56, 66), Alpha-11 (HPV34, 73), Alpha-13 (HPV54) and Alpha-3 (HPV61). Virology 516:86-101
Lang Kuhs, Krystle A; Lin, Shih-Wen; Hua, Xing et al. (2018) T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study. PLoS One 13:e0178167
Clarke, Megan A; Gradissimo, Ana; Schiffman, Mark et al. (2018) Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women. Clin Cancer Res 24:2194-2202
Mirabello, Lisa; Clarke, Megan A; Nelson, Chase W et al. (2018) The Intersection of HPV Epidemiology, Genomics and Mechanistic Studies of HPV-Mediated Carcinogenesis. Viruses 10:
Usyk, Mykhaylo; Zolnik, Christine P; Patel, Hitesh et al. (2017) Novel ITS1 Fungal Primers for Characterization of the Mycobiome. mSphere 2:
Gradíssimo, Ana; Burk, Robert D (2017) Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention. Expert Rev Mol Diagn 17:379-391
Mirabello, Lisa; Yeager, Meredith; Yu, Kai et al. (2017) HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. Cell 170:1164-1174.e6
Rodríguez, Ana Cecilia; Ávila, Carlos; Herrero, Rolando et al. (2017) Cervical cancer incidence after screening with HPV, cytology, and visual methods: 18-Year follow-up of the Guanacaste cohort. Int J Cancer 140:1926-1934
Chen, Zigui; Ho, Wendy C S; Boon, Siaw Shi et al. (2017) Ancient Evolution and Dispersion of Human Papillomavirus 58 Variants. J Virol 91:
Harari, Ariana; Chen, Zigui; Rodríguez, Ana Cecilia et al. (2016) Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections. J Infect Dis 213:939-47

Showing the most recent 10 out of 109 publications